Frequent Loss-of-Heterozygosity in CRISPR-Cas9-edited Early Human Embryos
DR. GREGORIO ALANIS-LOBATO
Gregorio obtained a BEng degree in Computer Systems Engineering at the National Polytechnic Institute in Mexico before moving to KAUST in Saudia Arabia to pursue MSc and PhD degrees in Computer Science and Computational Biology, respectively. Then, he became a postdoctoral fellow at the IMB in Mainz, Germany, where he developed methods to study the architecture of the human protein interactome. As a postdoctoral fellow at The Francis Crick Institute in London, he took advantage of multiomics datasets to map the regulatory networks driving the first cell fate decisions in the early human embryo. In addition, he developed pipelines to evaluate the presence of unintended on-target events in CRISPR-Cas9-edited human embryos.
Gregorio is now a Principal Computational Biologist at Boehringer Ingelheim Pharma, where he's applying his expertise in multiomics data integration and network biology to support the drug target discovery pipelines in the Central Nervous System and Research Beyond Borders departments.